Press Releases

Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers YAVNE, Israel, July 03, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,

YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by

On track to initiate EscharEx ® Phase III study in fourth quarter 2023 NexoBrid ® U.S. launch expected in early third quarter 2023 Cash of over $57 million; Operating cash runway through profitability Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, May 30, 2023 (GLOBE

Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time YAVNE, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its

Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension YAVNE, Israel, May 09, 2023 (GLOBE NEWSWIRE) --  MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic

Data to be highlighted in oral and poster presentations YAVNE, Israel , April 26, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic solutions for tissue repair, today announced the Company will present updated

2022 total revenues of $26.5 million FDA approval of NexoBrid ® in December 2022 ; U.S. commercial availability expected in the second quarter of 2023 EscharEx ® Phase III protocol design is under review by the FDA; study to be initiated in the second half of 2023 C ash position of $66 million ,

YAVNE, Israel , March 16, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company specializing in next-generation biotherapeutic solutions for tissue repair and regeneration, is pleased to announce the appointment of Ms.

Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development Appoints Alicia Torrenova, as Vice President of European Operations Both b ring extensive leadership experience and expertise in wound care and r egenerative medicine YAVNE, Israel, March 06, 2023 (GLOBE

Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time YAVNE, Israel, March 02, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,